NIH Reporter #11413914

Research and Development Services for HIV Integrase Inhibitors and Histone Variant Synthesis

The Division of Basic Sciences at the National Cancer Institute (NCI) is seeking specialized research and development services to advance anti-AIDS drug discovery and epigenetic studies. - Government Buyer: - National Cancer Institute (NCI), Division of Basic Sciences - Products/Services Requested: - Research and development of HIV integrase inhibitors (1 lot) - Synthesis of histone variants for epigenetic studies (1 lot) - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Unique/Notable Requirements: - Focus on compounds with potential therapeutic applications against HIV/AIDS - Emphasis on histone variant synthesis for epigenetic research - No specific bid response format, licensing, or technical standards detailed - Technical Context: - HIV integrase inhibitors are key targets for anti-AIDS drug development - Histone variants are important for understanding epigenetic mechanisms

Description

This procurement involves research and development of HIV integrase inhibitors and histone variants, focusing on compounds with potential therapeutic applications against HIV/AIDS and epigenetic studies. The project includes two main line items: HIV Integrase Inhibitors Development and Histone Variant Synthesis. The solicitation is issued by the Division of Basic Sciences - NCI, United States. No specific bid response format, licensing requirements, or important dates are provided.

View original listing